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Summary
Background Trastuzumab targets the extracellular domain of the HER2 protein. Adding trastuzumab to chemotherapy 
for patients with early-stage, HER2-positive breast cancer reduces the risk of recurrence and death, but is associated 
with cardiac toxicity. We investigated the long-term benefits and risks of adjuvant trastuzumab on breast cancer 
recurrence and cause-specific mortality.
Methods We did a collaborative meta-analysis of individual patient data from randomised trials assessing chemotherapy 
plus trastuzumab versus the same chemotherapy alone. Randomised trials that enrolled women with node-negative 
or node-positive, operable breast cancer were included. We collected individual patient-level data on baseline 
characteristics, dates and sites of first distant breast cancer recurrence and any previous local recurrence or second 
primary cancer, and the date and underlying cause of death. Primary outcomes were breast cancer recurrence, breast 
cancer mortality, death without recurrence, and all-cause mortality. Standard intention-to-treat log-rank analyses, 
stratified by age, nodal status, oestrogen receptor (ER) status, and trial yielded first-event rate ratios (RRs).
Findings Seven randomised trials met the inclusion criteria, and included 13 864 patients enrolled between 
February, 2000, and December, 2005. Mean scheduled treatment duration was 14·4 months and median follow-up 
was 10·7 years (IQR 9·5 to 11·9). The risks of breast cancer recurrence (RR 0·66, 95% CI 0·62 to 0·71; p<0·0001) and 
death from breast cancer (0·67, 0·61 to 0·73; p<0·0001) were lower with trastuzumab plus chemotherapy than with 
chemotherapy alone. Absolute 10-year recurrence risk was reduced by 9·0% (95% CI 7·4 to 10·7; p<0·0001) and 
10-year breast cancer mortality was reduced by 6·4% (4·9 to 7·8; p<0·0001), with a 6·5% reduction (5·0 to 8·0; 
p<0·0001) in all-cause mortality, and no increase in death without recurrence (0·4%, –0·3 to 1·1; p=0·35). The 
proportional reduction in recurrence was largest in years 0–1 after randomisation (0·53, 99% CI 0·46 to 0·61), with 
benefits persisting through years 2–4 (0·73, 0·62 to 0·85) and 5–9 (0·80, 0·64 to 1·01), and little follow-up beyond 
year 10. Proportional recurrence reductions were similar irrespective of recorded patient and tumour characteristics, 
including ER status. The more high risk the tumour, the larger the absolute reductions in 5-year recurrence (eg, 5·7% 
[95% CI 3·1 to 8·3], 6·8% [4·7 to 9·0], and 10·7% [7·7 to 13·6] in N0, N1–3, and N4+ disease).
Interpretation Adding trastuzumab to chemotherapy for early-stage, HER2-positive breast cancer reduces recurrence 
of, and mortality from, breast cancer by a third, with worthwhile proportional reductions irrespective of recorded 
patient and tumour characteristics. 
Funding Cancer Research UK, UK Medical Research Council.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 
4.0 license.
Introduction 
Amplification of the HER2 gene (also known as ERBB2) 
is present in 10–20% of tumours in patients with early-
stage breast cancer and is associated with aggressive 
cancers and an increased risk of disease recurrence.1,2 
Trastu zumab, a humanised IgG1 mono clonal antibody 
that targets the extracellular domain of the HER2 protein, 
improves progression-free survival and over all survival 
when administered in combination with chemotherapy 
in HER2-positive metastatic breast cancer.3 Substantial 
benefits are also seen with trastuzumab added to 
chemotherapy in non-metastatic breast cancer.4–10 Hence, 
trastuzumab combined with chemotherapy is now a 
standard treatment for both metastatic and early-stage, 
HER2-positive breast cancer.
HER2 status is most reliably ascertained by in-situ 
hybridisation using probes to label the number of gene 
copies of HER2 and the chromosome 17 centromere 
(CEP17), with most trials accepting a HER2 to CEP17 
ratio of at least 2·0 as positive.11 Alternatively, immuno-
histochemical staining of the HER2 protein can be used, 
with 3+ on a scale of 0, 1+, 2+, and 3+ considered as 
positive, and in-situ hybridisation used to confirm HER2 
status for tumours that are 2+.
However, it is not clear how the level of HER2 amplifi-
cation, tumour characteristics, in particular oestrogen 
receptor (ER) status, or other patient risk factors 
influence the magnitude and duration of treatment 
benefit. Trastuzumab is expensive and can be associated 
with cardiac toxicity, particularly when administered with 
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anthracyclines.3 In this meta-analysis, we aimed to 
evaluate the long-term benefits and risks of trastuzumab 
on breast cancer recurrence and cause-specific mortality, 
and whether these effects vary by patient characteristics 
or types of tumour.
Methods 
Study design and participants 
Methods of identifying trials, data collection, checking, 
analysis, and presentation for this collaborative meta-
analysis of individual patient-level data are as described 
in previous EBCTCG reports,12–15 and conform to the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (Individual Patient Data).16
Trials were eligible if they began before Jan 1, 2010, and 
randomly assigned women with node-negative or node-
positive, operable breast cancer to either chemotherapy 
(adjuvant or neoadjuvant) plus trastuzumab or to the 
same chemotherapy alone. Trials of trastuzumab added to 
other biological therapies (eg, trials comparing lapatinib, 
pertuzumab, or neratinib with or without trastuzumab) 
were not eligible. The lead investigators of all identified, 
eligible trials were asked during 2016–19 to supply 
information for each individual patient on randomisation 
date; allocated treatment; age; menopausal status; body-
mass index (BMI); tumour diameter, grade, histology, and 
spread to loco-regional lymph nodes; ER, progesterone 
receptor (PR), and HER2 receptor test scores; cell 
proliferation (Ki-67); dates and sites of first distant breast 
cancer recurrence and any previous local recurrence or 
second primary cancer; and the date and underlying cause 
of death.
Primary outcomes were any recurrence of invasive 
breast cancer (distant, loco-regional, or new primary in the 
contralateral breast), breast cancer mortality, death without 
recurrence, and all-cause mortality. Prespecified primary 
subgroup investigations were by site of recurrence; 
concurrent or sequential trastuzumab and chemotherapy; 
level of HER2 amplification; age; ER status; PR status; 
nodal status; tumour diameter, grade, histology (ie, ductal 
or lobular); BMI; proliferation index (Ki-67 <10%, 10–19%, 
or ≥20%); and follow-up period (years 0–1, 2–4, 5–9, ≥10).
Statistical analysis 
Statistical methods for checking and analysing data are 
described in previous EBCTCG reports,12–15 and in the 
statistical analysis plan (appendix). Time-to-event analyses 
were stratified by age, ER status, trial, and, except for 
studies including neoadjuvant trastuzumab, nodal status. 
Each analysis compared all women randomly assigned, 
regardless of treatment compliance (yielding intention-to-
treat analyses). Log-rank statistics were used to estimate 
the ratio of the annual event rates in the trastuzumab and 
control groups and its confidence interval; 95% CIs were 
used for meta-analyses and 99% CIs were used for 
individual trials or subgroups. Breast cancer mortality rate 
ratios (RRs) were estimated by subtracting log-rank 
statistics for mortality without recurrence from those of 
overall mortality, which avoids the need to identify which 
deaths after recurrence were from breast cancer.14 Forest 
plots and Kaplan-Meier graphs describe the separate trials 
and their combined results, and tests for heterogeneity13 
explore whether proportional risk reductions vary by trial, 
or by patient or tumour-related characteristics. Sensitivity 
Research in context
Evidence before this study
Amplification of the HER2 gene is present in 10–20% of tumours 
in patients with early-stage breast cancer and is associated with 
aggressive cancers and an increased risk of disease recurrence. 
The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)’s 
ongoing extensive searches of bibliographic databases, 
including MEDLINE, Embase, the Cochrane Library, and meeting 
abstracts, up to March 31, 2020, identified seven trials 
comparing chemotherapy plus trastuzumab, a humanised IgG1 
monoclonal antibody that targets the extracellular domain of 
the HER2 protein, with the same chemotherapy alone for early-
stage, HER2-positive breast cancer. Individual trials reported 
substantial benefits with trastuzumab; however, cardiac toxicity 
was increased and it was unclear how the level of HER2 
amplification, tumour characteristics (eg, oestrogen receptor 
[ER] status), or other patient risk factors influence the 
magnitude and duration of benefit.
Added value of this study
This collaborative meta-analysis collated, checked, and analysed 
individual patient-level data from 13 864 women in 
seven randomised controlled trials. Trastuzumab reduced the 
rate of breast cancer recurrence by 34% and of breast cancer 
mortality by 33%, compared with chemotherapy alone. 
The average absolute reduction in the 10-year risk of breast 
cancer recurrence was 9·0%, with a 6·4% reduction in the 
10-year risk of dying from breast cancer, and no increase in 
deaths unrelated to breast cancer. The proportional reductions 
in recurrence were similar for ER-positive and ER-negative 
tumours, and did not differ significantly by other patient or 
tumour characteristics, including the level of HER2 
amplification, for patients considered to be HER2-positive.
Implications of all the available evidence
Adding trastuzumab to chemotherapy for patients 
with early-stage, HER2-positive breast cancer reduces 
recurrence of and mortality from breast cancer by a third, 
with worthwhile proportional benefits irrespective of recorded 
patient and tumour characteristics.
See Online for appendix
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analyses to investigate the effect of crossover to trastu-
zumab censored all women in the HERA trial on the date 
when crossover to trastuzumab was offered to control 
patients. Statistical analyses used in-house FORTRAN 
programmes.
Role of the funding source 
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results 
Individual patient-level data were obtained from all 
seven identified, relevant trials (table),4–10 providing data 
for 13 864 women with early-stage, HER2-positive 
breast cancer who had been randomly assigned to 
receive chemotherapy plus trastuzumab or chemo-
therapy alone between February, 2000, and December, 
2005. Of these women, 3685 (26·6%) had breast cancer 
recurrence. 2738 (19·7%) deaths occurred, of which 
347 (12·7%) were from causes unrelated to breast 
cancer and without recorded disease recurrence. 
Median follow-up was 10·7 years (IQR 9·5–11·9). Trial 
inclusion criteria were HER2-positive tumours, with 
most trials requiring that these should be either lymph 
node-positive or high-risk if node-negative (generally 
defined as grade 3, tumour >1 cm if ER-negative or 
>2 cm if ER-positive; table). HER2 status was based on 
local immunohistochemistry or fluorescence in-situ 
hybrid isation testing, with some studies requiring 
central laboratory confirmation.
Sequential 12-week anthracycline followed by 12-week 
taxane chemotherapy regimens were used in the 
NSABP trial B-31 (2119 [15·3%] of 13 864 patients),4 
NCCTG trial N9831 (3505 [25·3%]),4 and BCIRG 006 
trial (2147 [15·5%]).9 Patients in the NOAH trial 
(235 [1·7%] patients)7 were given concurrent taxane 
and anthracycline, then taxane alone followed by 
cyclophosphamide–methotrexate–fluorouracil. FinHER 
(231 [1·7%] patients)6 included a randomisation to 
docetaxel or vinorelbine before anthra cyclines, and 
PACS 04 (528 [3·8%] patients)8 randomly assigned 
patients to fluorouracil–epirubicin–cyclo phos phamide 
or to epirubicin plus docetaxel. The choice of chemo-
therapy was not mandated in the HERA study 
(5099 [36·8%] patients), with 94% receiving anthra-
cyclines and 26% receiving a taxane in addition to an 
anthracycline.5 BCIRG 006 included a non-anthra-
cycline (docetaxel–carboplatin–trastuzumab) group, 
which was excluded from the main analyses as there 
was no control group receiving the same chemotherapy. 
Comparing the docetaxel–carboplatin–trastuzumab 
group with the anthracycline and docetaxel control 
group would have shown similar benefits from adding 
trastuzumab as those in the included trials (appendix 
p 20). In all trials, endocrine therapy was recommended 
in hormone receptor-positive disease.
Except for the NOAH trial,7 chemotherapy plus 
trastuzumab was administered after surgery. In HERA, 
PACS-04, and one group in NCCTG trial N9831, 
trastuzumab was commenced after completion of all 
chemotherapy. In other trials, trastuzumab was started 
after any anthracycline courses and given concurrently 
with taxane (or vinorelbine for 120 [52%] of FinHER 
patients) chemotherapy. Duration of treatment was 
12 months in all trials except for FinHER,6 which tested 
9 weeks of trastuzumab. The HERA trial also included a 
24-month trastuzumab treatment group,5 which was 
included in the primary analyses of trastuzumab (any 
duration) versus no trastuzumab. Thus, mean scheduled 
treatment duration across all trials was 14·4 months. 
Following presentation of early analyses in June, 2005, 
884 (52·1%) patients in the control group of HERA10 and 
382 (36·0%) patients in the control group of NSABP trial 
B-314 crossed over to receive trastuzumab (at median 
periods of 23 months from randomisation for HERA and 
17 months for NSABP trial B-31). There were few 
crossovers in the other trials.
Figure 1 shows the year started, study name, treatment 
comparison, log-rank statistics, and the ratio of annual 
event rates for each trial. Pooled analysis of all trials 
found a highly significant reduction in recurrence 
(RR 0·66, 95% CI 0·62 to 0·71; p<0·0001; figure 1) and 
breast cancer mortality (0·67, 0·61 to 0·73; p<0·0001; 
appendix p 7) with chemotherapy plus trastuzumab 
compared with chemotherapy alone. There was no 
significant heterogeneity between the seven trial results 
for recurrence or breast cancer mortality (p=0·21). The 
average absolute reduction in 10-year risk of recurrence 
was 9·0% (95% CI 7·4 to 10·7; p<0·0001) with a 
6·4% (4·9 to 7·8; p<0·0001) reduction in 10-year breast 
cancer mortality, a 6·5% (5·0 to 8·0; p<0·0001) reduction 
in all-cause mortality, and no increase in death without 
recurrence (0·4%, –0·3 to 1·1; p=0·35; figure 2; 
appendix pp 3–11). Subgroup analyses of breast cancer 
recurrence (local or distant, excluding contralateral), 
distant recurrence, and breast cancer mortality are shown 
in figure 3 and the appendix (pp 15–17). Trastuzumab 
reduced distant recurrence (RR 0·63, 99% CI 
0·57 to 0·70) and local recurrence (0·72, 0·59 to 0·89), 
but not contralateral breast cancer incidence (0·93, 
0·68 to 1·26; figure 3). There was little or no reduction in 
the incidence of brain metastases as the first site of 
distant recurrence (RR 0·91, 95% CI 0·73 to 1·13; 
p=0·40), a significantly lesser effect of trastuzumab 
than on distant recurrence at other sites (0·60, 
0·55 to 0·65; p<0·0001; appendix p 18).
The largest proportional reduction in recurrence was 
in years 0–1 (RR 0·53, 99% CI 0·46–0·61) with smaller 
proportional reductions in years 2–4 (0·73, 0·62–0·85) 
and years 5–9 (0·80, 0·64–1·01), and little follow-up 
beyond year 10 (figure 3). There were similar proportional 
reductions in risk of recurrence for ER-negative and 
ER-positive cancers (RR 0·62, 95% CI 0·56−0·69 vs 0·67, 
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0·60−0·74; figure 4). The recurrence rates in the first 2 
years were higher for ER-negative than for ER-positive 
cancers (appendix p 12), but were higher for ER-positive 
than for ER-negative in years 5–9. Hence, the average 
absolute reductions in 10-year recurrence risk with 
trastuzumab were similar for women with ER-negative 
(10·1%, 95% CI 7·7−12·5) and ER-positive disease (7·8%, 
5·5−10·1; figure 4). The average absolute reductions in 
10-year breast cancer mortality were 6·9% (4·8−9·1) for 
ER-negative tumours and 5·1% (3·2−7·0) for ER-positive 
tumours (appendix p 13). The proportional reductions in 
recurrence were greater in ER-positive, PR-negative 
tumours than for ER-positive, PR-positive tumours 
(RR 0·55, 95% CI 0·45−0·67 vs 0·76, 0·67−0·86; 
appendix p 14).
The proportional reduction in recurrence did not vary 
by age, BMI, duration of trastuzumab treatment, or 
traditional histopathological features (including tumour 
size, nodal status, tumour grade, or histological subtype), 
although there were relatively few women older than 
70 years, or with low-grade or lobular cancers (figure 3). 
In the few women with Ki-67 scores, there was no 
indication that efficacy varied with increasing proliferation 
index (figure 3).
In three trials, individual patient HER2 to CEP17 ratios 
were available from central pathology fluorescence 
in-situ hybridisation tests, with tumours with a ratio of at 
least 2·0 deemed to be HER2-positive. Figure 3 shows 
the reductions in risk of recurrence subdivided by finer 
categories of the HER2 to CEP17 ratio, suggesting no 
effect in the few patients with HER2 to CEP17 ratios of 
less than 2·0, and no significant trend of increasing 
benefit with increasing HER2 to CEP17 ratios above this 
threshold.
Figure 5 shows the 5-year risk of recurrence in different 
nodal status groups. Although the proportional reduction 
was similar across groups, the absolute reduction in 
5-year risk was greatest in patients with more involved 
nodes (5·7%, 95% CI 3·1−8·3 in N0; 6·8%, 4·7−9·0 in 
N1–3; and 10·7%, 7·7−13·6 in ≥N4 disease) because of 
their higher absolute risk of recurrence.
The reduction in recurrence in trials that administered 
trastuzumab concurrently with chemotherapy did not 
differ significantly from that in trials where it was given 
sequentially after completion of chemotherapy (RR 0·61, 
99% CI 0·53–0·70 for concurrent trastuzumab vs 0·69, 
0·61–0·78 for sequential trastuzumab; heterogeneity 
p=0·083; figure 3). In HERA, the largest sequential 
treatment trial, trastuzumab was offered to control 
patients, which might have attenuated the benefits of 
trastuzumab. In sensitivity analyses censoring all women 
in the HERA trial on the date when crossover to 
trastuzumab was offered to control patients, the average 
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Figure 1: Recurrence (distant, local, or contralateral) in trials testing trastuzumab versus control
A=doxorubicin (adriamycin). C=cyclophosphamide. D=docetaxel. E=epirubicin. F= fluorouracil. M=methotrexate. P=paclitaxel. Tr=trastuzumab. Vin=vinorelbine. q1=once weekly. q3=once every three 
weeks. q4=once every four weeks. *For balance, control patients in three-way trials or trial strata count twice in subtotals and in final total of events or patients.
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trastuzumab increased from 9·0% to 10·6% (appendix 
p 21). To minimise the effects of crossover, we compared 
the recurrence reductions seen with concurrent versus 
sequential trastuzumab in years 0–4 from randomisation, 
which showed a significantly larger reduction with 
concurrent treatment than with sequential treatment 
(p=0·02; appendix p 22). This indirect comparison is 
supported by the direct randomised com parison between 
concurrent and sequential trastuzumab in the NCCTG 
trial N9831, in which there were fewer distant recurrences 
(RR 0·78, 95% CI 0·63–0·97; p=0·026) and breast cancer 
deaths (0·76, 0·60–0·96, p=0·023) with concurrent 
trastuzumab than with sequential trastuzumab (appendix 
pp 23–24).
Overall, there was no apparent increase in deaths 
without breast cancer recurrence in the trastuzumab 
group (RR 0·90, 95% CI 0·72–1·12; p=0·35; appendix 
p 19). Similarly, there was no apparent increase in 
cardiovascular mortality (RR 1·23, 95% CI 0·73–2·06; 
p=0·44) or in deaths from new cancers at sites other than 
the breast (0·79, 0·54–1·17; p=0·24). However, there 
were more deaths unrelated to breast cancer in the first 
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Figure 2: Effect of trastuzumab versus control on recurrence and mortality
10-year cumulative risk of any recurrence (ie, distant, local, or contralateral; A), breast cancer mortality (B), death without any recurrence (C), and death from any 
cause (D). Breast cancer mortality rates calculated by total rate (events/woman-years) – rate in women without recurrence. Error bars are 95% CIs. O–E=observed 
minus expected. RR=rate ratio. V=variance of O–E. 
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Figure 3: Subgroup analyses of the effect of trastuzumab
All analyses, except for site of first recurrence, include any loco-regional or distant recurrence but exclude contralateral disease. ER=oestrogen receptor. 
PR=progesterone receptor.  
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year with chemotherapy plus trastuzumab than with 
chemotherapy alone (0·37% [31/8299] vs 0·16% [13/8328]; 
RR 2·15, 95% CI 1·11–4·14; p=0·023; appendix p 8). No 
particular cause of death explained this excess 
(appendix p 19). Of the 414 deaths without recorded 
recurrence, 72 (17%) were from unknown causes; 
however, these were unrelated to treatment allocation or 
TNM stage (appendix p 25), so are included with the 
deaths unrelated to breast cancer. The risk of death 
unrelated to breast cancer in the first year following 
randomisation appeared to be no greater in trials with 
concurrent chemotherapy plus trastuzumab (0·34% 
[11/3251] with trastuzumab vs 0·22% [7/3195] with 
control) than in trials with sequential chemotherapy 
followed by trastuzumab (0·43% [20/4607] with trastu-
zumab vs 0·13% [6/4468] with control; appendix p 19).
Patient-level data on cardiac toxicity were available from 
just one trial; the cardiac and non-cardiac toxicity reported 
in individual trial publications is summarised in the 
appendix (pp 26–29). The incidence of congestive heart 
failure and asymptomatic decrease in left ventri cular 
ejection fraction, usually resulting in treatment discon-
tinuation, was consistently higher in the trastu zumab 
group than in the control group, but the proportion 
of patients affected was low (appendix pp 26–29). Few 
fatal toxic events were reported with no excess in the 
trastuzumab group (appendix pp 26–29).
Discussion 
This meta-analysis substantiates that—for patients with 
operable HER2-positive breast cancer—the addition of 
trastuzumab to chemotherapy further reduces recurrence 
of, and mortality from, breast cancer during the first 
decade of follow-up by about a third. For the patient 
population in the trials in this analysis, this finding 
translates, on average, into a 10-year absolute reduction 
of 9·0% in recurrence and of 6·4% in breast cancer 
mortality, compared with chemotherapy alone. These 
reductions were achieved despite substantial crossover 
from control to trastuzumab in two trials; therefore, the 
benefits might have been larger with perfect compliance. 
The greatest effect was on distant recurrence, although 
local recurrence was also reduced; however, there was no 
apparent effect on the incidence of new contralateral 
breast cancers.
Subgroup analyses by conventional pathological features 
indicated similar proportional reductions in recurrence, 
irrespective of nodal status, tumour grade, tumour 
diameter, and histological subtype. Trastuzumab produced 
similar proportional reductions in recurrence of ER-
positive and ER-negative disease, as did chemotherapy 
alone in previous meta-analyses.12,17 Similar to HER2-
negative disease, the risk of early (years 0–4) recurrence 
was higher for HER2-positive, ER-negative tumours than 
for HER2-positive, ER-positive tumours. However, late 
(years 5–9) recurrences are more likely in ER-positive than 
in ER-negative disease, even though patients with 
ER-positive disease were scheduled to receive at least 
5 years of endocrine therapy.18
As the proportional reductions in different subgroups 
were similar, there were greater absolute reductions in risk 
among patients with node-positive disease than among 
those with node-negative disease because of their higher 
absolute risk of recurrence. Nevertheless, the absolute 
benefits were substantial, even in the patients with node-
negative disease entered into these trials, suggesting 
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Figure 4: Effect of trastuzumab versus control on recurrence by ER status 
Recurrence analyses include any loco-regional or distant recurrence, but exclude contralateral disease. Error bars are 95% CIs. ER=oestrogen receptor. O–E=observed 
minus expected. RR=rate ratio. V=variance of O–E.
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appreciable benefits from the addition of trastuzumab to 
chemotherapy for all patients with HER2-positive disease 
fit enough to receive systemic treatment.
Only three studies included central fluorescence in-
situ hybridisation testing and, in these, benefits from 
trastuzumab did not increase with increasing HER2 to 
CEP17 ratio above the conventional cutoff of 2·0. There 
was no apparent benefit in tumours with HER2 to CEP17 
ratios below the 2·0 threshold for HER2 positivity, 
consistent with the reduced efficacy of trastuzumab in 
low HER2 tumours in the NSABP trial B-47;19 however, 
there were not enough patient numbers to assess 
whether, for example, 1·8 or 2·2 might be a better cutoff 
for HER2 positivity than might 2·0.
Starting trastuzumab concurrently with the taxane 
component of chemotherapy seemed at least as 
efficacious as giving it sequentially (ie, starting only after 
completing all chemotherapy), which is consistent with 
data suggesting that giving trastuzumab concurrently 
with chemotherapy is synergistic.20 Sequential admin-
istration does allow for assessment of cardiac function 
(an eligibility requirement for HERA) following chemo-
therapy; however, in patients for whom cardiac risk is not 
a major concern, giving trastuzumab concurrently with 
Figure 5: Effect of trastuzumab versus control on recurrence by nodal status
Recurrence analyses include any loco-regional or distant recurrence, but exclude contralateral disease. Error bars are 95% CIs. O–E=observed minus expected. RR=rate 
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the taxane cycles seems to be advisable given that benefits 
emerge early: the biggest impact on recurrence was seen 
in the first 2 years after randomisation and there was no 
apparent increase in toxicity with concurrent taxane 
chemotherapy and trastuzumab, compared with sequen-
tial treatment.
We found no overall increase in mortality from causes 
unrelated to breast cancer. Nevertheless, there were more 
deaths without recurrence in the first year after random-
isation with trastuzumab than with control, which was 
not explained by administering trastuzumab concurrently 
with chemotherapy. This finding could well be due to 
chance, as the difference is spread over several different 
causes. However, even if the apparent excess risk is real, 
the excess number of these deaths was 30 times smaller 
than the number of deaths from breast cancer prevented. 
Despite the well documented adverse effects of trastu-
zumab on cardiac function, the number of deaths from 
cardiovascular causes was low and not significantly 
higher in patients treated with chemotherapy plus 
trastuzumab than in those treated with chemotherapy 
alone, neither overall nor in the first year. Longer 
follow-up of these trials is needed to evaluate safety more 
than 10 years after treatment. Individual patient-level 
data on non-fatal toxicity, including cardiac morbidity, 
was not available for this meta-analysis, but data from 
individual trial reports indicate that serious toxicity is 
rare, even though most trials administered trastuzumab 
after anthracycline chemotherapy regimens. Although 
more effective, this type of regimen is associated with 
greater toxicity than is non-anthracycline chemotherapy.9,12 
The incidence of non-breast second primary cancers did 
not appear to be reduced by trastuzumab, indicating that 
the reduced incidence of such cancers in the initial 
NSABP trial B-31 and the NCCTG trial N9831 report4 
might have been a chance finding.
Most trials in this meta-analysis treated patients with 
trastuzumab for 12 months and the recurrence reductions 
were largest during this treatment period. Somewhat less 
benefit was found during years 2–4 and 5–9, after any 
trastuzumab treatment had been completed, raising the 
possibility that extended treatment with trastuzumab 
might have been more efficacious. Nevertheless, in the 
HERA trial, 2 years of trastuzumab did not appear to 
provide any greater benefit than 1 year of treatment.21 
Switching to another HER2-directed therapy, neratinib, 
after 1 year of trastuzumab appeared more effective than 
continuing trastuzumab.22 We could not compare the 
efficacy of trastuzumab for 1 year versus less than 1 year 
as only the FinHER trial tested a shorter treatment time 
of 9 weeks. We included this small trial in these analyses, 
even though this treatment duration appears inadequate.23 
However, the overall results would not be materially 
different if it were excluded. Three trials comparing 1 year 
versus 6 months of trastuzumab treatment, which were 
not included in this meta-analysis, all reported fewer 
recurrences with 12 months than with 6 months of 
trastuzumab, but had conflicting interpretations as to 
whether or not 12 months of treatment was more effective 
than 6 months.24–26 Despite these trials not being included 
in our main analysis, we did a post-hoc meta-analysis of 
their published results, which showed fewer recurrences 
with 12 months than with 6 months of trastuzumab 
(appendix p 30); however, an individual patient-level data 
meta-analysis of these trials is needed to help clarify the 
benefits and risks of extended trastuzumab treatment.
The efficacy of trastuzumab could be enhanced by 
adding other HER-directed therapies, such as lapatinib 
or pertuzumab,27,28 and by giving combination HER2-
directed therapy before surgery.29 Adapting treatment 
according to initial tumour response is another approach, 
as in the KATHERINE trial, in which switching to 
trastuzumab–emtansine (an antibody–drug conjugate) 
was more effective than continuing trastuzumab in 
patients with residual disease following neoadjuvant 
chemotherapy plus trastuzumab.30 Further understanding 
of how cancer biology affects outcome, such as the 
relevance of tumour-infiltrating lymphocytes or tumour 
genomics,31 might also help to individualise treatment 
approaches.
In summary, this meta-analysis confirms that breast 
cancer recurrence and mortality can be reduced by a third 
by adding 1 year of trastuzumab treatment to adjuvant 
chemotherapy in patients with early-stage, HER2-positive 
breast cancer. The proportional reduction was unaffected 
by any of the measured tumour or patient characteristics. 
Because optimal anthracycline and taxane-based chemo-
therapy schedules also reduce the risk of breast cancer 
mortality by about a third, regardless of HER2 status or 
other characteristics,12,17 the combination of chemotherapy 
plus trastuzumab for HER2-positive breast cancer could 
reduce the risk of death from breast cancer by about 50%, 
compared with receiving neither chemotherapy nor 
trastuzumab.
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